[{"id":"7cd7c85e-4e1b-46fd-8491-96d1bcc8b391","acronym":"IMGN632-0802","url":"https://clinicaltrials.gov/study/NCT04086264","created_at":"2021-01-18T20:00:09.580Z","updated_at":"2025-02-25T12:27:19.012Z","phase":"Phase 1/2","brief_title":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","source_id_and_acronym":"NCT04086264 - IMGN632-0802","lead_sponsor":"AbbVie","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • pivekimab sunirine (PVEK)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 218","initiation":"Initiation: 11/06/2019","start_date":" 11/06/2019","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-24"},{"id":"9e19f934-321f-4e6c-b066-71f0217f0bae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03041688","created_at":"2021-01-18T14:58:33.453Z","updated_at":"2025-02-25T12:26:38.524Z","phase":"Phase 1","brief_title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03041688","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • CD4","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 wild-type","tags":["TP53 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-24"},{"id":"23ac8e6c-a9b5-4a23-995c-206f44787ba3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02890329","created_at":"2021-01-18T14:11:09.765Z","updated_at":"2025-02-25T13:48:17.623Z","phase":"Phase 1","brief_title":"Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","source_id_and_acronym":"NCT02890329","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" High ALC","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e High ALC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • azacitidine • decitabine • CS1002 (ipilimumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/05/2017","start_date":" 09/05/2017","primary_txt":" Primary completion: 10/24/2022","primary_completion_date":" 10/24/2022","study_txt":" Completion: 08/19/2025","study_completion_date":" 08/19/2025","last_update_posted":"2025-02-21"},{"id":"af7d23ec-b13e-4076-9480-1b329c34d370","acronym":"DelVIN","url":"https://clinicaltrials.gov/study/NCT05717621","created_at":"2023-02-08T17:00:09.181Z","updated_at":"2025-02-25T15:27:53.533Z","phase":"Phase 1","brief_title":"Clinical Trial With Local Decitabine Treatment of HPV-Induced VIN Grade 2/3 (DelVIN)","source_id_and_acronym":"NCT05717621 - DelVIN","lead_sponsor":"ViMREX GmbH","biomarkers":" CDKN2A","pipe":" | ","alterations":" CDKN2A overexpression","tags":["CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 03/28/2023","start_date":" 03/28/2023","primary_txt":" Primary completion: 01/17/2025","primary_completion_date":" 01/17/2025","study_txt":" Completion: 01/17/2025","study_completion_date":" 01/17/2025","last_update_posted":"2025-02-11"},{"id":"c84b4894-7b72-40e5-b7d9-73619eecd885","acronym":"22P.205","url":"https://clinicaltrials.gov/study/NCT05564650","created_at":"2022-10-03T15:56:48.447Z","updated_at":"2025-02-25T15:35:52.261Z","phase":"Phase 1/2","brief_title":"Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT05564650 - 22P.205","lead_sponsor":"Thomas Jefferson University","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 01/12/2023","start_date":" 01/12/2023","primary_txt":" Primary completion: 04/10/2026","primary_completion_date":" 04/10/2026","study_txt":" Completion: 04/10/2026","study_completion_date":" 04/10/2026","last_update_posted":"2025-02-11"},{"id":"e3936c5c-e8c6-4488-bd75-cc3cc84c9df4","acronym":"NCI-2018-01789","url":"https://clinicaltrials.gov/study/NCT03661307","created_at":"2021-01-18T17:57:55.790Z","updated_at":"2025-02-25T15:25:53.725Z","phase":"Phase 1/2","brief_title":"Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT03661307 - NCI-2018-01789","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion","tags":["TP53 • FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Vanflyta (quizartinib) • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 10/31/2018","start_date":" 10/31/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-10"},{"id":"74bef0ec-e64e-4efc-a1bb-a54c18f7a818","acronym":"","url":"https://clinicaltrials.gov/study/NCT04220684","created_at":"2021-01-18T20:32:37.858Z","updated_at":"2025-02-25T16:32:03.029Z","phase":"Phase 1","brief_title":"Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML","source_id_and_acronym":"NCT04220684","lead_sponsor":"Sumithira Vasu","biomarkers":" IL21","pipe":"","alterations":" ","tags":["IL21"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • decitabine • fludarabine IV • SAR445419"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 06/11/2020","start_date":" 06/11/2020","primary_txt":" Primary completion: 10/22/2024","primary_completion_date":" 10/22/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"a6261b4d-283f-45db-9b03-c83871bfbd02","acronym":"","url":"https://clinicaltrials.gov/study/NCT02957968","created_at":"2021-01-18T14:31:51.880Z","updated_at":"2025-02-25T16:05:24.919Z","phase":"Phase 2","brief_title":"Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca","source_id_and_acronym":"NCT02957968","lead_sponsor":"Virginia Commonwealth University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • HER-2 negative + HR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • doxorubicin hydrochloride • azacitidine • albumin-bound paclitaxel • cyclophosphamide • decitabine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 01/24/2017","start_date":" 01/24/2017","primary_txt":" Primary completion: 08/04/2022","primary_completion_date":" 08/04/2022","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-11-11"},{"id":"c3e37946-e4b9-4544-a60c-995c415bbbe7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06563778","created_at":"2025-02-26T10:28:05.577Z","updated_at":"2025-02-26T10:28:05.577Z","phase":"Phase 2","brief_title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","source_id_and_acronym":"NCT06563778","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • Adcetris (brentuximab vedotin) • Epidaza (chidamide) • bendamustine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-08-21"},{"id":"8357d385-35ac-4d87-9fa3-47078a947c30","acronym":"","url":"https://clinicaltrials.gov/study/NCT02650986","created_at":"2021-01-18T12:54:24.654Z","updated_at":"2024-07-02T16:34:26.492Z","phase":"Phase 1/2","brief_title":"Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1","source_id_and_acronym":"NCT02650986","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" BRAF • CTAG1B","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • cyclophosphamide • decitabine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/14/2017","start_date":" 07/14/2017","primary_txt":" Primary completion: 03/04/2021","primary_completion_date":" 03/04/2021","study_txt":" Completion: 07/14/2032","study_completion_date":" 07/14/2032","last_update_posted":"2024-06-13"},{"id":"576b9aae-2746-4ca3-a5a4-167bcd5465e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06393361","created_at":"2024-05-04T04:28:35.114Z","updated_at":"2024-07-02T16:34:27.321Z","phase":"Phase 2","brief_title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.","source_id_and_acronym":"NCT06393361","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • ifosfamide • etoposide IV • decitabine • pegylated liposomal doxorubicin • Adcetris (brentuximab vedotin) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-06-11"},{"id":"4dcb8f8b-2695-4bef-a128-38e8217912be","acronym":"","url":"https://clinicaltrials.gov/study/NCT05177731","created_at":"2022-01-05T13:53:46.126Z","updated_at":"2024-07-02T16:34:36.990Z","phase":"Phase 3","brief_title":"Venetoclax + Decitabine vs. \"7+3\" Induction Chemotherapy in Young AML","source_id_and_acronym":"NCT05177731","lead_sponsor":"Chen Suning","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • decitabine • idarubicin hydrochloride"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 188","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-07"},{"id":"1b47f0da-b2fe-4983-9f86-298118e2f79d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04277442","created_at":"2021-01-18T20:46:25.519Z","updated_at":"2024-07-02T16:34:37.901Z","phase":"Phase 1","brief_title":"Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT04277442","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Venclexta (venetoclax) • azacitidine • decitabine • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1","initiation":"Initiation: 03/11/2020","start_date":" 03/11/2020","primary_txt":" Primary completion: 09/06/2022","primary_completion_date":" 09/06/2022","study_txt":" Completion: 06/04/2025","study_completion_date":" 06/04/2025","last_update_posted":"2024-06-06"},{"id":"553a2aa0-3616-4887-9128-31724ad68197","acronym":"","url":"https://clinicaltrials.gov/study/NCT06129734","created_at":"2023-11-14T02:16:19.811Z","updated_at":"2024-07-02T16:34:37.496Z","phase":"Phase 1/2","brief_title":"Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant","source_id_and_acronym":"NCT06129734","lead_sponsor":"Benjamin Tomlinson","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • decitabine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 12/27/2024","primary_completion_date":" 12/27/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-06"},{"id":"9259cd2b-7d10-4e29-a71a-448de9ccec7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02257138","created_at":"2021-01-18T10:36:04.617Z","updated_at":"2024-07-02T16:35:05.273Z","phase":"Phase 1/2","brief_title":"Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia","source_id_and_acronym":"NCT02257138","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Jakafi (ruxolitinib) • decitabine"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/12/2015","start_date":" 02/12/2015","primary_txt":" Primary completion: 03/19/2021","primary_completion_date":" 03/19/2021","study_txt":" Completion: 03/19/2021","study_completion_date":" 03/19/2021","last_update_posted":"2024-05-08"},{"id":"3a37bc3c-8cd8-4398-97d2-6d24383dcff4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04188405","created_at":"2021-01-18T20:24:56.671Z","updated_at":"2024-07-02T16:35:06.506Z","phase":"Phase 2","brief_title":"Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT04188405","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["ABL1 • BCR • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Iclusig (ponatinib) • azacitidine • decitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/17/2020","start_date":" 05/17/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-02"},{"id":"264c1f17-e960-45e7-a8ad-1364b1706dfb","acronym":"NKX101-101","url":"https://clinicaltrials.gov/study/NCT04623944","created_at":"2022-04-15T16:52:42.805Z","updated_at":"2024-07-02T16:35:10.692Z","phase":"Phase 1","brief_title":"NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS","source_id_and_acronym":"NCT04623944 - NKX101-101","lead_sponsor":"Nkarta Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • decitabine • fludarabine IV • NKX101"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 09/21/2020","start_date":" 09/21/2020","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2039","study_completion_date":" 07/01/2039","last_update_posted":"2024-04-09"},{"id":"401066f5-9ad7-4b59-a3d6-fadca2f51a94","acronym":"PRECISE","url":"https://clinicaltrials.gov/study/NCT02664181","created_at":"2021-01-18T12:59:07.227Z","updated_at":"2024-07-02T16:35:10.884Z","phase":"Phase 2","brief_title":"Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial","source_id_and_acronym":"NCT02664181 - PRECISE","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" EGFR • ALK","pipe":"","alterations":" ","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • decitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 06/06/2017","start_date":" 06/06/2017","primary_txt":" Primary completion: 07/02/2019","primary_completion_date":" 07/02/2019","study_txt":" Completion: 08/15/2024","study_completion_date":" 08/15/2024","last_update_posted":"2024-04-09"},{"id":"ec361a88-10be-462e-b8c7-8fa193d6a067","acronym":"","url":"https://clinicaltrials.gov/study/NCT03418038","created_at":"2021-01-18T16:51:47.082Z","updated_at":"2024-07-02T16:35:11.929Z","phase":"Phase 2","brief_title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT03418038","lead_sponsor":"Mayo Clinic","biomarkers":" IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation","tags":["IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-02"},{"id":"cb11cd54-0bac-4f20-bf14-95c5e18524bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04187703","created_at":"2022-04-24T09:01:41.679Z","updated_at":"2024-07-02T16:35:15.464Z","phase":"Phase 1","brief_title":"5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies","source_id_and_acronym":"NCT04187703","lead_sponsor":"Benjamin Tomlinson","biomarkers":" ABL1 • BCR • CD14 • DCK • DNMT1 • ITGAM • NT5C","pipe":" | ","alterations":" Chr del(5q)","tags":["ABL1 • BCR • CD14 • DCK • DNMT1 • ITGAM • NT5C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/16/2020","start_date":" 11/16/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-11"},{"id":"db802908-d352-4788-a1a5-ab4e959f4c3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03009240","created_at":"2024-03-12T22:20:15.146Z","updated_at":"2024-07-02T16:35:15.595Z","phase":"Phase 1","brief_title":"Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia","source_id_and_acronym":"NCT03009240","lead_sponsor":"City of Hope Medical Center","biomarkers":" MIR155 • NFKB1","pipe":" | ","alterations":" miR-155 expression • NFKB1 expression","tags":["MIR155 • NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e miR-155 expression • NFKB1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/21/2017","start_date":" 08/21/2017","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-03-08"},{"id":"78f0c593-d1fd-41d9-ba78-7be4edf097a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06046313","created_at":"2023-09-21T15:11:03.917Z","updated_at":"2024-07-02T16:35:16.284Z","phase":"Phase 2","brief_title":"Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS","source_id_and_acronym":"NCT06046313","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 10/19/2023","start_date":" 10/19/2023","primary_txt":" Primary completion: 10/19/2025","primary_completion_date":" 10/19/2025","study_txt":" Completion: 10/19/2026","study_completion_date":" 10/19/2026","last_update_posted":"2024-03-05"},{"id":"9a1bd20f-9971-453e-a407-90e121f47cfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04697940","created_at":"2021-01-19T20:49:56.659Z","updated_at":"2024-07-02T16:35:20.405Z","phase":"Phase 1/2","brief_title":"Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL","source_id_and_acronym":"NCT04697940","lead_sponsor":"Han weidong","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • decitabine • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-02-07"},{"id":"04099553-7b26-44dd-86c3-9c0ad9dbc7fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03445858","created_at":"2021-01-18T16:59:28.292Z","updated_at":"2024-07-02T16:35:22.149Z","phase":"Phase 1","brief_title":"Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults","source_id_and_acronym":"NCT03445858","lead_sponsor":"Children's Hospital Medical Center, Cincinnati","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • decitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 02/12/2018","start_date":" 02/12/2018","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 01/12/2025","study_completion_date":" 01/12/2025","last_update_posted":"2024-01-25"}]